- Home
- ATEX vs ABEO Comparison
ATEX vs ABEO Comparison
Compare ATEX & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- ABEO
- Stock Information
- Founded
- ATEX 1997
- ABEO 1974
- Country
- ATEX United States
- ABEO United States
- Employees
- ATEX N/A
- ABEO N/A
- Industry
- ATEX Telecommunications Equipment
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- ATEX Telecommunications
- ABEO Health Care
- Exchange
- ATEX Nasdaq
- ABEO Nasdaq
- Market Cap
- ATEX 408.7M
- ABEO 332.0M
- IPO Year
- ATEX N/A
- ABEO 1980
- Fundamental
- Price
- ATEX $21.13
- ABEO $6.26
- Analyst Decision
- ATEX Buy
- ABEO Strong Buy
- Analyst Count
- ATEX 2
- ABEO 6
- Target Price
- ATEX $64.00
- ABEO $18.00
- AVG Volume (30 Days)
- ATEX 174.1K
- ABEO 611.9K
- Earning Date
- ATEX 08-12-2025
- ABEO 08-19-2025
- Dividend Yield
- ATEX N/A
- ABEO N/A
- EPS Growth
- ATEX N/A
- ABEO N/A
- EPS
- ATEX N/A
- ABEO N/A
- Revenue
- ATEX $6,031,000.00
- ABEO N/A
- Revenue This Year
- ATEX $5.17
- ABEO N/A
- Revenue Next Year
- ATEX $2.92
- ABEO $322.37
- P/E Ratio
- ATEX N/A
- ABEO N/A
- Revenue Growth
- ATEX 43.90
- ABEO N/A
- 52 Week Low
- ATEX $20.61
- ABEO $3.93
- 52 Week High
- ATEX $42.91
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- ATEX 30.74
- ABEO 47.50
- Support Level
- ATEX $21.73
- ABEO $6.18
- Resistance Level
- ATEX $22.26
- ABEO $6.94
- Average True Range (ATR)
- ATEX 0.83
- ABEO 0.27
- MACD
- ATEX 0.10
- ABEO -0.05
- Stochastic Oscillator
- ATEX 22.18
- ABEO 18.07
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.